CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 442 enrolled
Drug / intervention
ARQ-151 0.3% cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04211389
NCT04211389Phase 3Completed
CompareCT.gov

A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis

Arcutis Biotherapeutics, Inc.·interventional·Posted Dec 26, 2019·Updated Dec 7, 2022

In Brief

A Phase 3 clinical trial evaluating ARQ-151 0.3% cream and ARQ-151 vehicle cream for Chronic Plaque Psoriasis. Completed, enrolled 442 participants across 39 sites in 2 countries.

Detailed Summary

This study will assess the safety and efficacy of ARQ-151 cream vs placebo applied once a day for 56 days by subjects with chronic plaque psoriasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedDec 26, 2019
Enrollment StartDec 17, 2019
Primary CompletionNov 23, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.5 years ago

Interventions

ARQ-151 0.3% creamdrug

ARQ-151 0.3% cream

ARQ-151 vehicle creamdrug

ARQ-151 vehicle cream